Health Canada Approves IMCIVREE for Acquired Hypothalamic Obesity
RYTM sits 33% above its 52-week low of $74.5.
Summary
Health Canada approved IMCIVREE (setmelanotide) for weight management in adults and children 4+ with acquired hypothalamic obesity. This opens a new commercial market for Rhythm, following recent approvals in the UK and Japan. The company's Q2 revenue of $71.3M was driven by the U.S. launch of the same indication, and this approval expands the global footprint. The approval is a material regulatory milestone that supports the growth narrative.
At the time of this announcement, RYTM was trading at $98.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.